Back to homepage

Tag "second-line"

Second-line treatment options in hepatocellular carcinoma

Authors: Donatella Marino MD, Clizia Zichi MD, Marco Audisio MD, Elisa Sperti MD, Massimo Di Maio MD

This review discusses the evidence on second-line options for hepatocellular carcinoma, focusing on the latest results that are currently refining the treatment scenario.

More▸

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications

Authors: Nicola Personeni MD, Tiziana Pressiani MD, Armando Santoro MD, Lorenza Rimassa MD

Over the past ten years, sorafenib has been the only systemic agent approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) and in a second-line setting, most investigational drugs have failed to provide better survival outcomes than placebo. However, in 2016, data from the RESORCE trial, a phase 3 study evaluating regorafenib in HCC patients who experience disease progression after first-line treatment with sorafenib, have shown a 2.8-month median survival benefit over placebo (10.6 versus 7.8 months).

More▸